Boston Scientific ($BSX) announced an update on their ongoing clinical study. Study OverviewThis global Boston Scientific trial, officially titled ...

Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with AFib.

After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt™ PFA System to treat patients battling atrial fibrillation (AFib). Abbott will soon begin ...

The Volt pulsed-field ablation (PFA) system (Abbott) has been approved by the US Food and Drug Administration for the treatment of patients with atrial fibrillation (AF), according to a Monday ...

PANAMA CITY — A local hospital continues working to provide its patients with up-to-date procedures. According to a press release from Ascension Sacred Heart Bay, the facility now offers pulsed field ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW ORLEANS -- A ...

Catheter ablation was favored for rhythm control in atrial fibrillation (Afib or AF) when considering its psychological benefits over medical therapy alone, the REMEDIAL randomized trial showed.

Johnson & Johnson MedTech today announced its sponsorship of a new PFA data collection platform from the Heart Rhythm Society ...

Radiofrequency-based ablation for atrial fibrillation appears more effective than previously shown in clinical trials. Using real-world data, a new study found that the procedure eliminated atrial ...

Atrial fibrillation (AFib) can lead to blood clots, stroke, heart failure, and other heart-related complications. New consumer patient research from the Dallas-based American Heart Association found ...